Trial Profile
The Impact of Imprinting and Repeated Influenza Vaccination on Adaptive Immunity, Transcriptomics, and Metabolomics
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 14 Jul 2022
Price :
$35
*
At a glance
- Drugs GSK 2321138A (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Acronyms FLU2
- 24 Jan 2022 Phase of the trial is changed from phase-1 to phase-4.
- 24 Jan 2022 Status changed from suspended to discontinued. The study closed prior to completing year 3 of the study due to the COVID-19 pandemic.
- 16 Aug 2020 Status changed from recruiting to suspended due to COVID-19